ORIGINAL RESEARCH article
Front. Med.
Sec. Hematology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1640245
This article is part of the Research TopicAdvancing Therapeutic Strategies for Relapsed/Refractory Acute Lymphoblastic LeukemiaView all articles
Serum Proteome Profiling Identified thrombospondin-1 and lactoferrin as Biomarkers of Relapsed Multiple Myeloma
Provisionally accepted
- 1Department of comprehensive oncology, National Clinical Research Center for Cancer, Beijing, China
- 2Tsinghua University School of Life Sciences, Beijing, China
- 3Department of hematology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Multiple myeloma (MM) remains an incurable hematologic malignancy characterized by inevitable relapse despite advances in novel therapeutics.Identifying reliable biomarkers for relapsed/refractory MM (RRMM) is crucial to improving clinical outcomes. In this study, we performed a comprehensive proteomic analysis of bone marrow and peripheral serum samples from newly diagnosed MM (NDMM), RRMM, and MM remission patients, along with healthy controls. Using tandem mass tag (TMT)-labeled quantitative mass spectrometry, we quantified over 1,000 serum proteins and identified thrombospondin-1 (THBS1) and lactoferrin (LTF) as significantly downregulated in the bone marrow serum of RRMM patients. ELISA validation confirmed these findings, demonstrating that THBS1 and LTF levels were markedly reduced in both bone marrow and peripheral serum of RRMM patients compared to NDMM, remission, and healthy control groups. Our integrated proteomic and biochemical analyses suggest that the THBS1/LTF protein signature may serve as a predictive biomarker for MM relapse, offering potential clinical utility in disease monitoring and therapeutic stratification.
Keywords: THBS1, LTF, Relapsed/refractory myeloma, Proteomics, serum biomarker
Received: 03 Jun 2025; Accepted: 26 Aug 2025.
Copyright: © 2025 Wu, Guo, Deng and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Wenming Chen, Department of hematology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.